[Micrometastases in bone marrow of patients with cancers in the head and neck area].
Individual disseminated epithelial tumour cells were detected in bone marrow aspirates in 41 of 108 patients (37%) with squamous cell cancer of the head and neck region by an immunocytochemical technique based on monoclonal antibodies raised against the cytokeratin No. 19. In the clinical stage I (T1N0M0) tumour cells were detected only in 26.3% of the patients, whereas in stage IV (T4N0M0, T(all)N2-3M0, T(all)N(all)M1) almost twice as many patients (47.7%) presented with tumour cells in the bone marrow. Apparently, grade of differentiation of the tumour (grading) had no influence on the spread of single tumour cells. An influence of the different localisations of the primary tumour on tumour cell spread or the rate of tumour recurrence cannot as yet be discovered. Cytokeratin No. 19 expressing cells were not detectable in the bone marrow of 18 patients with non-malignant disease. Seventy-three patients were included in a follow-up study with a mean observation time of 25 months (range: 4-52 months). The presence of epithelial cells at the time of primary treatment appears to indicate a significantly higher risk of development of local or distant tumour recurrences (p = 0.01). Of 46 patients initially exhibiting no tumour cells in the bone marrow, only 14 had a clinical recurrence. Whereas 17 of 27 patients who presented with tumour cells in the bone marrow developed either a local tumour recurrence or distant metastases in different organs. Patients presenting with bone marrow tumour cells showed a significantly shorter disease-free survival than those without (p = 0.002).(ABSTRACT TRUNCATED AT 250 WORDS)
Wollenberg
B
B
Klinik und Poliklinik für Hals-, Nasen- und Ohrenkranke, LMU München.
Ollesch
A
A
Maag
K
K
Funke
I
I
Wilmes
E
E
D014408:Biomarkers, Tumor / Q000032:analysis; D001707:Biopsy, Needle; D001853:Bone Marrow / Q000473:pathology*; D001859:Bone Neoplasms / Q000473:pathology / Q000556:secondary*; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000556:secondary*; D006258:Head and Neck Neoplasms / Q000473:pathology*; D006801:Humans; D007124:Immunoenzyme Techniques; D007633:Keratins / Q000032:analysis; D017493:Leukocyte Common Antigens / Q000032:analysis; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D011379:Prognosis
D014408:Biomarkers, Tumor; D007633:Keratins; D017493:Leukocyte Common Antigens